Korlym mifepristone regulatory update

Corcept said FDA will not require a REMS for Korlym mifepristone to treat Cushing's syndrome. The progesterone and cortisol receptor antagonist has a PDUFA date of Feb. 17. Cushing's syndrome is a hor...